GE HealthCare once again joins the world’s top medical and academic institutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting to discuss healthcare landscape and announce new precision care tools to meet providers’ most pressing needs – namely the accessibility of technologies and solutions for the global practice of personalized medicine.

More than half of the world’s population is underserved and lacks access to essential health services,^iv and two-thirds have no access to diagnostic imaging.^v Yet even those who have these services and systems within reach may struggle to receive necessary scans due to the challenges healthcare providers often face in reliably sourcing commercial PET tracers – leaving many patients and medical centers around the world without recourse. These shortfalls, in addition to ongoing healthcare resource and staff shortages,^vi challenge the adoption of precision care globally.

“It’s not enough to develop cutting-edge solutions if they aren’t also made more accessible to clinicians and patients around the world,” shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. “While there is still much work to be done, we are proud to offer a variety of technologies that can evolve with healthcare system needs and help support a patient’s entire care journey – from the systems required to create the radiotracers used to diagnose and monitor disease, to the imaging equipment used for a noninvasive look at a patient’s anatomy and treatment monitoring, to the software optimized to measure lesion size and dose. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”

As clinicians seek to practice more personalized medicine – including Theranostics, a type of precision care that combines diagnostics and therapy – they increasingly look to leverage imaging techniques that more accurately inform diagnoses and measure functional and molecular responses to therapy.